ClinicalTrials.gg
CompletedNCT03324061Updated Jun 3, 2021

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

A Phase 1 interventional study of Fulvestrant for Injectable Suspension and Faslodex (Reference) in Pharmacokinetics, sponsored by Eagle Pharmaceuticals, Inc.. Completed at 12 sites in United States. Open to female participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Eagle Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 4 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Study summary

Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable Suspension compared to the reference product, Faslodex in healthy female subjects.

Read the detailed description

This is a Phase 1, open-label, parallel group study in healthy female subjects. The study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single dose of Fulvestrant for Injectable Suspension vs. the reference drug, Faslodex, administered in the gluteal muscle.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Eagle Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18 kg/m2 to 32 kg/m2
  • Body weight of at least 50 kg at screening
  • Good health as determined by evaluations
  • Negative serum pregnancy test
  • Subjects who are naturally for at least 12 consecutive months with a follicle-stimulating hormone level at Screening of ≥40 mIU/mL
  • Subjects who are peri-menopausal and experiencing at least one of specified symptoms of menopause (eg, hot flashes, mood swings, night sweats, and others)
  • Negative urine test for drugs of abuse
  • Negative urine test for antibody, HBsAG, and at Screening
  • Women of must agree to consistently practice throughout the duration of the study and continue to do so for 1 year after receiving study drug by one of the following methods: abstinence, condom, diaphragm or cervical cap with spermicide, intrauterine device or male partner had previously undergone a vasectomy as declared in medical history

Exclusion criteria

Exclusion Criteria:

  • Recent history (6 months) or current evidence of any (uncontrolled) disorder including hepatic, renal, cardiovascular, psychological, pulmonary, metabolic, endocrine, neurologic, infectious, gastrointestinal, hematologic or oncologic disease, or other medical conditions that may interfere with the subject completing the study
  • Lab test results outside the normal range at Screening or Day 1 considered clinically significant by the Investigator
  • Use of hormonal replacement therapy within 6 months prior to randomization an/or current use of oral pill or patch as contraceptive method throughout the study
  • Concomitant medication that can affect bleeding
  • Recent history (6 months) or presence of an abnormal that, in the opinion of the Investigator, is clinically significant
  • Subjects with interval duration >470 milliseconds
  • History of alcoholism or drug addiction within 1 year prior to Day 1
  • History of allergy or a known sensitivity to product components of fulvestrant Test and Reference formulations
  • \<60 mL/minute based on the Cockcroft-Gault equation
  • Blood donation of 500 mL or more or a significant loss of blood within 56 days prior to Day 1
  • Previous exposure to fulvestrant
  • Familial relationship with another study participant
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Fulvestrant for Injectable Suspension

    Fulvestrant for Injectable Suspension (500 mg/vial)

    Drug: Fulvestrant for Injectable Suspension

  • Active comparator
    Faslodex (R)

    Faslodex (250 mg/mL)

    Drug: Faslodex (Reference)

Interventions

  • Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area

  • Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters

    Area under the concentration-time curve(AUC)

    Time frame: Day 0 through Day 140

07

Study locations

12 sites
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Quotient Sciences
    Miami, Florida 33126, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • New Horizon Clinical Research
    Cincinnati, Ohio 45242, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
  • Optimal Research, LLC
    Austin, Texas 78705, United States
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03324061
Lead sponsor
Eagle Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Nov 30, 2017
Primary completion
Jul 12, 2018
Completion
Jul 12, 2018
Last update
Jun 3, 2021

Study contacts

Adrian J Hepner, MD, PhD
study director · Eagle Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion